A novel inhaled multi-pronged attack against respiratory bacteria

European Journal of Pharmaceutical Sciences

Volumn 70, Issue , 2015, Pages 37-44

  Lee, Sie Huey ^a,b   Teo, Jeanette ^c   Heng, Desmond ^a   Zhao, Yanli ^b,d   Ng, Wai Kiong ^a   Chan, Hak Kim ^e   Teng, Tan Li ^a   Tan, Reginald B H ^a,f  

^a INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES   (Singapore)

^b Nanyang Technological University   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e UNIVERSITY OF SYDNEY   (Australia)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antiinfectives; Combinatorial therapy; Dry powder inhaler; Mucoactives; Quorum sensing; Synergy

Indexed keywords

AMBROXOL; CIPROFLOXACIN; GATIFLOXACIN; ANTIINFECTIVE AGENT;

AEROSOL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRY POWDER; DRY POWDER INHALER; IN VITRO STUDY; MUCOCILIARY CLEARANCE; MUCUS SECRETION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; SPRAY DRYING; SURFACE PROPERTY; BACTERIAL INFECTIONS; DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; PROCEDURES; RESPIRATORY TRACT INFECTIONS; SPUTUM; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRY POWDER INHALERS; HUMANS; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTIONS; SPUTUM; X-RAY DIFFRACTION;

EID: 84922585037     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.01.005     Document Type: Article

References (48)

1. S. Al-Dgither, S.N. Alvi, and M.M. Hammami Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma J. Pharm. Biomed. Anal. 41 2006 251 255
2. R. Balsamo, L. Lanata, and C.G. Egan Mucoactive drugs Eur. Respir. Rev. 19 2010 127 133
3. D. Bilton Cystic fibrosis Medicine 36 2008 273 278
4. R. Chait, A. Craney, and R. Kishony Antibiotic interactions that select against resistance Nature 446 2007 668 671
5. R.N. Chernish, and S.D. Aaron Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis Curr. Opin. Pulm. Med. 9 2003 509 515
6. N.Y.K. Chew, and H.-K. Chan Use of solid corrugated particles to enhance powder aerosol performance Pharm. Res. 18 2001 1570 1577
7. N.Y.K. Chew, B.Y. Shekunov, H.H.Y. Tong, A.H.L. Chow, C. Savage, J. Wu, and H.-K. Chan Effect of amino acids on the dispersion of disodium cromoglycate powders J. Pharm. Sci. 94 2005 2289 2300
8. N.Y.K. Chew, P. Tang, H.-K. Chan, and J.A. Raper How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm. Res. 22 2005 148 152
9. A.L. Coates, P.D. Allen, C.F. MacNeish, S.L. Ho, and L.C. Lands Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis Chest 119 2001 1123 1130
10. T.M. Crowder, J.A. Rosati, J.D. Schroeter, A.J. Hickey, and T.B. Martonen Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development Pharm. Res. 19 2002 239 245
11. J. Davies, and D. Davies Origins and evolution of antibiotic resistance Microbiol. Mol. Biol. Rev. 74 2010 417 433
12. A. Deep, U. Chaudhary, and V. Gupta Quorum sensing and bacterial pathogenicity: from molecules to disease J. Lab. Phys. 3 2011 4 11
13. Y.-H. Dong, L.-H. Wang, and L.-H. Zhang Quorum-quenching microbial infections: mechanisms and implications Philos. Trans. R. Soc. London, A 362 2007 1201 1211
14. G. Doring, S.P. Conway, H.G.M. Heijerman, M.E. Hodson, N. Hoiby, A. Smyth, and D.J. Touw Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus Eur. Respir. J. 16 2000 749 767
15. L. Ejim, M.A. Farha, S.B. Falconer, J. Wildenhain, B.K. Coombes, M. Tyers, E.D. Brown, and G.D. Wright Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy Nat. Chem. Biol. 7 2011 348 350
16. R.L. Elmore, M.E. Contois, J. Kelly, A. Noe, and A. Poirier Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs Clin. Ther. 18 1996 246 255
17. C.L. Haley, J.A. Colmer-Hamood, and A.N. Hamood Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium BMC Microbiol. 12 2012 181
18. D.J. Hassett, J. Cuppoletti, B. Trapnell, S.V. Lymar, J.J. Rowe, S.S. Yoon, G.M. Hilliard, K. Parvatiyar, M.C. Kamani, D.J. Wozniak, S.-H. Hwang, T.R. McDermott, and U.A. Ochsner Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways; rethinking antibiotic treatment strategies and drug targets Adv. Drug Delivery Rev. 54 2002 1425 1443
19. D.P. Heaf, G.J. Webb, and D.J. Matthew In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis Arch. Dis. Child. 58 1983 824 836
20. D. Heng, S.H. Lee, J.W. Kwek, W.K. Ng, H.-K. Chan, and R.B.H. Tan Assessing the combinatorial influence of climate, formulation and device on powder aerosolization using the Taguchi experimental design Powder Technol. 226 2012 253 260
21. D. Heng, S.H. Lee, W.K. Ng, H.-K. Chan, J.W. Kwek, and R.B.H. Tan Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization Int. J. Pharm. 452 2013 194 200
22. L. Kalan, and G.D. Wright Antibiotic adjuvants: multicomponent anti-infective strategies Expert Rev. Mol. Med. 13 2011 1 17
23. S.H. Lee, D. Heng, W.K. Ng, H.-K. Chan, and R.B.H. Tan Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy Int. J. Pharm. 403 2011 192 200
24. S.H. Lee, J. Teo, D. Heng, W.K. Ng, H.-K. Chan, and R.B.H. Tan Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation Eur. J. Pharm. Biopharm. 83 2013 275 284
25. S.H. Lee, J. Teo, D. Heng, Y. Zhao, W.K. Ng, H.-K. Chan, and R.B.H. Tan Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy J. Pharm. Sci. 103 2014 1115 1125
26. F. Li, W. Wang, L. Hu, L. Li, and J. Yu Effect of ambroxol on pneumonia caused by Pseudomonas aeruginosa with biofilm formation in an endotracheal intubation rat model Chemotherapy 57 2011 173 180
27. Q. Li, G. Yao, and X. Zhu High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery Neurocrit. Care 16 2012 267 272
28. P.D. Lister, D.J. Wolter, and N.D. Hanson Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms Clin. Microbiol. Rev. 22 2009 582 610
29. V. Lorian Antibiotics in Laboratory Medicine 2005 Williams and Wilkins Baltimore, MD
30. G. Loughlin, and H. Eigen Respiratory Disease in Children: Diagnosis and Management 1994 Williams and Wilkins Baltimore, MD
31. Q. Lu, J. Yu, X. Yang, J. Wang, L. Wang, Y. Lin, and L. Lin Ambroxol interferes with Pseudomonas aeruginosa quorum sensing Int. J. Antimicrob. Agents 36 2010 211 215
32. J.W. Mouton Combination therapy as a tool to prevent emergence of bacterial resistance Infection 27 1999 S24 S28
33. B.P. O'Sullivan, and S.D. Freedman Cystic fibrosis Lancet 373 2009 1891 1904
34. A. Oliver, R. Canton, P. Campo, F. Baquero, and J. Blazquez High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection Science 288 2000 1251 1253
35. F. Paganin, O. Bouvet, P. Chanez, D. Fabre, M. Galtier, P. Godard, F.B. Michel, and F. Bressolle Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation Biopharm. Drug Dispos. 16 1995 393 401
36. D. Paleari, G.A. Rossi, G. Nicolini, and D. Olivieri Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood Expert Opin. Drug Discov. 6 2011 1203 1214
37. F. Ratjen, and G. Doring Cystic fibrosis The Lancet 361 2003 681 689
38. J.R. Riordan, J.M. Rommens, B.-S. Kerem, N. Alon, R. Rozmahel, Z. Grzelczak, J. Zielenski, S. Lok, N. Plavsic, J.-L. Chou, M.L. Drumm, M.C. Iannuzzi, F.S. Collins, and L.-C. Tsui Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science 245 1989 1066 1072
39. D.F. Rogers Mucoactive agents for airway mucus hypersecretory diseases Respir. Care 52 2007 1176 1197
40. F. Tewes, K.J. Paluch, L. Tajber, K. Gulati, D. Kalantri, C. Ehrhardt, and A.M. Healy Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery Eur. J. Pharm. Biopharm. 85 2013 604 613
41. Tillotson, G.S., Theriault, N., 2013. New and alternative approaches to tackling antibiotic resistance. F1000Prime Reports 5, pp. 1-9.
42. D. Traini, and P.M. Young Delivery of antibiotics to the respiratory tract: an update Expert Opin. Drug Delivery 6 2009 897 905
43. L.-C. Tsui The cystic fibrosis transmembrane conductance regulator gene Am. J. Respir. Crit. Care Med. 151 1995 S47 S53
44. N.H. Valerius, C. Koch, and N. Hoiby Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment Lancet 338 1991 725 726
45. J. Watkins, J. Francis, and J.A. Kuzemko Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? Scand. J. Gastroenterol. 143 1988 81 85
46. K. Weiss, and J.R. Lapointe Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa Antimicrob. Agents Chemother. 39 1995 2411 2414
47. A.I. Wertheimer, and A. Morrison Combination drugs: innovation in pharmacotherapy Pharm. Ther. 27 2002 44 49
48. D. Worlitzsch, R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K.C. Meyer, P. Birrer, G. Bellon, J. Berger, T. Weiss, K. Botzenhart, J.R. Yankaskas, S. Randell, R.C. Boucher, and G. Doring Effects of reduced mucus oxygen concentration in airway pseudomonas infections of cystic fibrosis patients J. Clin. Investig. 109 2002 317 325